Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

United Therapeutics (UTHR) Other Non Operating Income (2016 - 2026)

United Therapeutics' Other Non Operating Income history spans 17 years, with the latest figure at $47.2 million for Q4 2025.

  • On a quarterly basis, Other Non Operating Income rose 1915.38% to $47.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $48.9 million, a 743.1% increase, with the full-year FY2025 number at $48.9 million, up 743.1% from a year prior.
  • Other Non Operating Income hit $47.2 million in Q4 2025 for United Therapeutics, up from $6.1 million in the prior quarter.
  • Over the last five years, Other Non Operating Income for UTHR hit a ceiling of $97.2 million in Q1 2021 and a floor of -$51.8 million in Q2 2022.
  • Historically, Other Non Operating Income has averaged $2.1 million across 5 years, with a median of -$1.6 million in 2023.
  • Biggest five-year swings in Other Non Operating Income: crashed 23400.0% in 2021 and later surged 1915.38% in 2025.
  • Tracing UTHR's Other Non Operating Income over 5 years: stood at -$28.8 million in 2021, then surged by 81.6% to -$5.3 million in 2022, then soared by 88.68% to -$600000.0 in 2023, then tumbled by 333.33% to -$2.6 million in 2024, then surged by 1915.38% to $47.2 million in 2025.
  • Business Quant data shows Other Non Operating Income for UTHR at $47.2 million in Q4 2025, $6.1 million in Q3 2025, and -$100000.0 in Q2 2025.